TY - JOUR
T1 - Transcatheter aortic valve implantation in low ejection fraction/low transvalvular gradient patients
T2 - the rule of 40
AU - Conrotto, Federico
AU - D’Ascenzo, Fabrizio
AU - Stella, Pieter
AU - Pavani, Marco
AU - Rossi, Marco Luciano
AU - Brambilla, Nedy
AU - Napodano, Massimo
AU - Covolo, Elisa
AU - Saia, Francesco
AU - Tarantini, Giuseppe
AU - Agostoni, Pierfrancesco
AU - Marzocchi, Antonio
AU - Presbitero, Patrizia
AU - Bedogni, Francesco
AU - Salizzoni, Stefano
AU - D’Amico, Maurizio
AU - Moretti, Claudio
AU - Rinaldi, Mauro
AU - Gaita, Fiorenzo
N1 - Publisher Copyright:
© 2017 Italian Federation of Cardiology. All rights reserved.
PY - 2017/2
Y1 - 2017/2
N2 - BACKGROUND: Several factors have been identified as predictors of events after transcatheter aortic valve implantation (TAVI) but the impact of left ventricular ejection fraction (LVEF) and mean transaortic gradient (MTG) is controversial. This multicenter study aimed to clarify the prognostic role of low LVEF and low MTG after TAVI. METHODS: From 2007 to 2012, 764 consecutive patients with severe symptomatic aortic valve stenosis underwent TAVI at participating hospitals. Patients were divided according to LVEF and MTG into four groups. RESULTS: Sixty-four patients had LVEF 40% or less and MTG less than 40?mmHg, 76 had LVEF 40% or less and MTG at least 40?mmHg, 163 had LVEF more than 40% and MTG less than 40?mmHg, 461 had LVEF more than 40% and MTG at least 40?mmHg. Two-year mortality was significantly higher in patients with low LVEF and low MTG, whereas it was similar in patients with low LVEF and high MTG, high LVEF and low MTG, and high LVEF and high MTG (51.3 vs. 22.4 vs. 23.3. vs. 25.5%, respectively; P?=?0.001). These results were confirmed by multivariate analysis, as the combination of low LVEF and low MTG (both less than 40) was identified as the stronger mid-term mortality predictor (hazard ratio 2.4, confidence interval 95% 1.4–3.9; P?=?0.001). CONCLUSION: At least one parameter between LVEF or MTG over 40 predicts a good prognosis for TAVI patients at mid-term follow-up, whereas those with both left ventricular dysfunction and low mean aortic pressure gradient are at high risk of all-cause death after TAVI.
AB - BACKGROUND: Several factors have been identified as predictors of events after transcatheter aortic valve implantation (TAVI) but the impact of left ventricular ejection fraction (LVEF) and mean transaortic gradient (MTG) is controversial. This multicenter study aimed to clarify the prognostic role of low LVEF and low MTG after TAVI. METHODS: From 2007 to 2012, 764 consecutive patients with severe symptomatic aortic valve stenosis underwent TAVI at participating hospitals. Patients were divided according to LVEF and MTG into four groups. RESULTS: Sixty-four patients had LVEF 40% or less and MTG less than 40?mmHg, 76 had LVEF 40% or less and MTG at least 40?mmHg, 163 had LVEF more than 40% and MTG less than 40?mmHg, 461 had LVEF more than 40% and MTG at least 40?mmHg. Two-year mortality was significantly higher in patients with low LVEF and low MTG, whereas it was similar in patients with low LVEF and high MTG, high LVEF and low MTG, and high LVEF and high MTG (51.3 vs. 22.4 vs. 23.3. vs. 25.5%, respectively; P?=?0.001). These results were confirmed by multivariate analysis, as the combination of low LVEF and low MTG (both less than 40) was identified as the stronger mid-term mortality predictor (hazard ratio 2.4, confidence interval 95% 1.4–3.9; P?=?0.001). CONCLUSION: At least one parameter between LVEF or MTG over 40 predicts a good prognosis for TAVI patients at mid-term follow-up, whereas those with both left ventricular dysfunction and low mean aortic pressure gradient are at high risk of all-cause death after TAVI.
KW - heart failure, mean transaortic gradient, severe aortic stenosis, transcatheter aortic valve implantation
UR - http://www.scopus.com/inward/record.url?scp=84966701433&partnerID=8YFLogxK
U2 - 10.2459/JCM.0000000000000402
DO - 10.2459/JCM.0000000000000402
M3 - Article
C2 - 27168140
AN - SCOPUS:84966701433
SN - 1558-2027
VL - 18
SP - 103
EP - 108
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
IS - 2
ER -